← Back to Screener
BeOne Medicines Ltd. American Depositary Shares (ONC)
Price$318.07
Favorite Metrics
Price vs S&P 500 (26W)-28.85%
Price vs S&P 500 (4W)4.28%
Market Capitalization$36.48B
All Metrics
Book Value / Share (Quarterly)$2.99
P/TBV (Annual)6.47x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)53.06%
Cash Flow / Share (Quarterly)$0.34
Payout Ratio (TTM)14.65%
Price vs S&P 500 (YTD)-11.69%
Gross Margin (TTM)85.99%
Net Profit Margin (TTM)-0.43%
EPS (TTM)$-0.03
10-Day Avg Trading Volume3.51M
EPS Excl Extra (TTM)$-0.03
Revenue Growth (5Y)55.91%
EPS (Annual)$-0.53
Dividend / Share (Annual)$0.04
ROI (Annual)-15.56%
Gross Margin (Annual)84.33%
Net Profit Margin (5Y Avg)-172.96%
Cash / Share (Quarterly)$2.96
Revenue Growth QoQ (YoY)41.14%
ROA (Last FY)-11.62%
Revenue Growth TTM (YoY)50.62%
EBITD / Share (TTM)$0.10
ROE (5Y Avg)-32.33%
Operating Margin (TTM)2.22%
Cash Flow / Share (Annual)$-0.49
P/B Ratio8.50x
P/B Ratio (Quarterly)10.33x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.83x
Net Interest Coverage (TTM)-132.16x
ROA (TTM)-0.33%
EV / EBITDA (TTM)239.14x
EPS Incl Extra (Annual)$-0.53
Current Ratio (Annual)1.81x
Quick Ratio (Quarterly)2.12x
3-Month Avg Trading Volume2.84M
52-Week Price Return20.61%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.86
P/S Ratio (Annual)9.16x
Asset Turnover (Annual)0.64x
52-Week High$346.00
Operating Margin (5Y Avg)-172.58%
EPS Excl Extra (Annual)$-0.53
CapEx CAGR (5Y)40.78%
26-Week Price Return-20.10%
Quick Ratio (Annual)1.52x
13-Week Price Return-21.66%
Total Debt / Equity (Annual)0.32x
Current Ratio (Quarterly)2.40x
Enterprise Value$35,659.255
Revenue / Share Growth (5Y)55.15%
Asset Turnover (TTM)0.78x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.31x
Pretax Margin (Annual)-15.30%
Cash / Share (Annual)$2.01
3-Month Return Std Dev42.49%
Gross Margin (5Y Avg)82.40%
Net Income / Employee (TTM)$-0
ROE (Last FY)-20.59%
Net Interest Coverage (Annual)-8.59x
EPS Basic Excl Extra (Annual)$-0.53
P/FCF (TTM)63.74x
Receivables Turnover (TTM)7.05x
EV / Free Cash Flow (TTM)73.40x
Total Debt / Equity (Quarterly)0.28x
EPS Incl Extra (TTM)$-0.03
Receivables Turnover (Annual)7.33x
ROI (TTM)-0.45%
P/S Ratio (TTM)6.99x
Pretax Margin (5Y Avg)-169.62%
Revenue / Share (Annual)$2.91
Tangible BV / Share (Annual)$2.43
Forward P/E46.11x
Price vs S&P 500 (52W)22.40%
Year-to-Date Return-8.71%
5-Day Price Return1.29%
EPS Normalized (Annual)$-0.53
ROA (5Y Avg)-21.52%
Net Profit Margin (Annual)-18.29%
Month-to-Date Return4.97%
EBITD / Share (Annual)$-0.39
Operating Margin (Annual)-15.29%
LT Debt / Equity (Annual)0.05x
P/CF (TTM)51.24x
ROI (5Y Avg)-27.54%
LT Debt / Equity (Quarterly)0.03x
EPS Basic Excl Extra (TTM)$-0.03
P/TBV (Quarterly)10.78x
P/B Ratio (Annual)6.16x
Dividend / Share (TTM)$0.06
Inventory Turnover (TTM)1.47x
Pretax Margin (TTM)2.22%
Book Value / Share (Annual)$2.55
Price vs S&P 500 (13W)-24.52%
Dividend Yield (TTM)0.22%
Beta0.64x
Revenue / Share (TTM)$3.40
ROE (TTM)-0.58%
52-Week Low$213.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ONCBeOne Medicines Ltd. American Depositary Shares | 6.99x | 50.62% | 85.99% | — | $318.07 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
BeOne Medicines is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes targeted cancer treatments. The company's portfolio includes BRUKINSA (a Bruton's tyrosine kinase inhibitor), sonrotoclax (a BCL2 inhibitor), and other proprietary therapeutics. BeOne generates revenue primarily from the sale of its biopharmaceutical products across multiple oncology indications.